(NASDAQ: JANX) Janux Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.43%.
Janux Therapeutics's earnings in 2025 is -$101,895,000.On average, 21 Wall Street analysts forecast JANX's earnings for 2025 to be -$123,062,413, with the lowest JANX earnings forecast at -$150,898,818, and the highest JANX earnings forecast at -$112,416,251. On average, 19 Wall Street analysts forecast JANX's earnings for 2026 to be -$178,530,721, with the lowest JANX earnings forecast at -$271,146,314, and the highest JANX earnings forecast at -$147,783,162.
In 2027, JANX is forecast to generate -$229,596,209 in earnings, with the lowest earnings forecast at -$351,311,311 and the highest earnings forecast at -$173,676,793.